文献速递胸部肿瘤

奥希替尼治疗携带罕见EGFR突变非小细胞肺癌的II期试验

Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).
PubMed 文献 · J Clin Oncol · 2019-12-11

韩国多中心单臂开放标签II期研究纳入37例携带罕见EGFR突变(除外19del、L858R、T790M及20插入)的转移或复发NSCLC患者,评估奥希替尼疗效与安全性。客观缓解率50%(18/36,95%CI 33%至67%),中位无进展生存8.2个月(95%CI 5.9至10.5个月),中位缓解持续时间11.2个月(95%CI 7.7至14.7个月),中位总生存未达到;不良事件以皮疹、瘙痒、食欲下降、腹泻和呼吸困难为主,均可管理。

要点

  • 奥希替尼在罕见EGFR突变NSCLC中客观缓解率达50%。
  • 中位无进展生存8.2个月,中位缓解持续时间11.2个月。
  • 不良事件以1-2级皮疹、瘙痒、腹泻等为主,总体可管理。

核心结论

  • 奥希替尼在携带罕见EGFR突变的NSCLC患者中显示出良好活性且毒性可控。

研究设计与样本

  • 多中心、单臂、开放标签II期研究(KCSG-LU15-09),于韩国开展,2016年3月至2017年10月入组37例患者。
  • 入组标准为组织学确诊的转移或复发NSCLC,携带除19外显子缺失、L858R、T790M及20外显子插入以外的EGFR突变。
  • 主要终点为客观缓解率,每6周按RECIST 1.1评估;次要终点包括无进展生存、总生存、缓解持续时间和安全性。

主要发现

  • 36例可评估患者中客观缓解率为50%(18/36,95%CI 33%至67%)。
  • 中位无进展生存期为8.2个月(95%CI 5.9至10.5个月),中位总生存未达到。
  • 中位缓解持续时间为11.2个月(95%CI 7.7至14.7个月)。
  • 突变类型分布:G719X 19例(53%)、L861Q 9例(25%)、S768I 8例(22%)、其他4例(11%)。
  • 任何级别不良事件包括皮疹11例(31%)、瘙痒9例(25%)、食欲下降9例(25%)、腹泻8例(22%)、呼吸困难8例(22%),均可控。

临床怎么用

  • 对于携带罕见EGFR突变(如G719X、L861Q、S768I)的NSCLC患者,奥希替尼可作为治疗选择。
  • 治疗期间应监测皮疹、瘙痒、食欲下降、腹泻和呼吸困难等不良事件,并给予相应管理。

局限性

  • 单臂设计,无对照组。
  • 样本量较小(37例),部分突变亚型病例数少。
  • 研究仅在韩国进行,人群代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS: This was a multicenter, single-arm, open-label, phase II study in Korea. Patients with histologically confirmed metastatic or recurrent NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R and T790M mutations, and exon 20 insertion were eligible for the study. The primary end point of objective response rate was assessed every 6 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary end points were progression-free survival, overall survival, duration of response, and safety. RESULTS: Between March 2016 and October 2017, 37 patients were enrolled. All were evaluable except one patient who withdrew consent after starting treatment. Median age was 60 years, and 22 (61%) were male. Among patients, 61% received osimertinib as first-line therapy. The mutations identified were G719X (n = 19; 53%), followed by L861Q (n = 9; 25%), S768I (n = 8; 22%), and others (n = 4; 11%). Objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%). Median progression-free survival was 8.2 months (95% CI, 5.9 to 10.5 months), and median overall survival was not reached. Median duration of response was 11.2 months (95% CI, 7.7 to 14.7 months). Adverse events of any grade were rash (n = 11; 31%), pruritus (n = 9; 25%), decreased appetite (n = 9; 25%), diarrhea (n = 8; 22%), and dyspnea (n = 8; 22%), but all adverse events were manageable. CONCLUSION: Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cho JH, Lim SH, An HJ, et al. Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09). J Clin Oncol. 2019. PMID: 31825714. doi:10.1200/JCO.19.00931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。